Intrauterine development, feto-placental function and pregnancy outcome after induction of ovulation with bromoergocryptine.
18 pregnancies occurred after treatment with bromoergocryptine in 17 patients who wished to conceive, but who suffered from anovulation of varying aetiology. The course of 15 pregnancies was uneventful. Three pregnancies ended in abortion. Nine of the 17 women had hyperprolactinemic amenorrhea. Furthermore, one woman had normoprolactinemic post-pill amenorrhea, another normoprolactinemic anovulatory oligomenorrhea and a third normoprolactinemic anovulatory regular menstruations. With the exception of one woman, all had galactorrhea. The courses of pregnancy were monitored by frequent ultrasound measurements of the fetal biparietal diameter, maternal urinary estriol excretion and radioimmunological measurements of plasma estrone, estradiol, unconjugated and immunoreactive estriol, progesterone, and HPL. All data were within the normal ranges and all babies were healthy at birth and had no teratogenic defects. The data prove the great value of bromoergocryptine in the treatment of hyperprolactinemic anovulation, sometimes even in the treatment of normoprolactinemic anovulation. Moreover, the results indicate no adverse effect on either the course or the outcome of pregnancy.
D000022:Abortion, Spontaneous / Q000150:complications; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D004964:Estriol / Q000097:blood / Q000652:urine; D004970:Estrone / Q000097:blood; D005260:Female; D006801:Humans; D010062:Ovulation Induction; D010928:Placental Lactogen / Q000097:blood; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood
D004970:Estrone; D001971:Bromocriptine; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D010928:Placental Lactogen; D004964:Estriol